{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:46:03Z","timestamp":1782708363599,"version":"3.54.5"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced sarcomas have limited systemic therapy options, but genomic profiling can uncover actionable mutations. This case series illustrates the promise and limitations of next-generation sequencing (NGS) and targeted therapies in clinical practice across three sarcoma histologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentations<\/jats:title>\n                    <jats:p>\n                      Case 1: A 36-year-old woman received local therapies for an angiosarcoma in her breast. Six months later, she developed osseous metastatic disease, and NGS revealed a\n                      <jats:italic>GOPC-ROS1<\/jats:italic>\n                      fusion. She had a partial response to crizotinib. This ROS1 inhibitor and one course of radiation for oligometastatic progression controlled her disease for 12 months. Subsequent lines of therapy included pembrolizumab for high PD-L1 status, with suspected hyperprogression. Repotrectinib was trialed to overcome her\n                      <jats:italic>ROS1 G2032R<\/jats:italic>\n                      resistance mutation, but it had limited efficacy. She ultimately succumbed to her disease. Case 2: A 30-year-old woman with Neurofibromatosis Type 1 developed a high-grade, ALK-rearranged peripheral malignant nerve sheath tumor at her left antecubital fossa. Following resection, pulmonary metastases were identified. RNA transcriptome analysis revealed an\n                      <jats:italic>EML4-ALK<\/jats:italic>\n                      rearrangement. She had a prolonged partial response to alectinib. The ALK inhibitor and two courses of radiation for oligoprogression have continued to control her disease at 48 months. Case 3: A 51-year-old woman with uterine leiomyosarcoma developed pulmonary metastases shortly after completing adjuvant radiation. NGS revealed a BRCA2 deep deletion. After progressing on multiple lines of systemic therapies, her widely metastatic disease has been controlled for 62 months with niraparib and local therapies for oligoprogression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Three patients with advanced sarcomas achieved partial responses to NGS-guided targeted therapies, with disease control lasting from 1 to over 5 years. Two cases involved novel, targetable mutations not previously identified in these sarcoma subtypes. However, the limitations of targeted therapies are highlighted by one patient\u2019s lack of response to a novel ROS1 G2032R-directed treatment, and another patient\u2019s repeated oligometastatic progression despite using an ALK inhibitor without resistance mutations. Simply suppressing a driver-mutation clone with targeted therapy may be insufficient for long-term disease control in sarcoma. Local therapies can be critical adjuvants in achieving improved outcomes for aggressive sarcomas. We recommend careful consideration of NGS testing for all sarcomas as we continue to explore their vast mutational landscape, response to targeted therapies, and mechanisms of resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1842108","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:26:43Z","timestamp":1782707203000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A case series on actionable genomic alterations guiding effective targeted therapy in rare sarcomas"],"prefix":"10.3389","volume":"16","author":[{"given":"Jamie L","family":"Zeal","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of North Carolina","place":["Chapel Hill, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G","family":"Woodcock","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of North Carolina","place":["Chapel Hill, NC, United States"]},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina","place":["Chapel Hill, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Y","family":"Chen","sequence":"additional","affiliation":[{"name":"University of North Carolina Medical Center, Department of Pharmacy","place":["Chapel Hill, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob N","family":"Stein","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of North Carolina","place":["Chapel Hill, NC, United States"]},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina","place":["Chapel Hill, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02771","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"41","author":"Heinrich","year":"2023","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00606-4","article-title":"New treatment strategies for advanced-stage gastrointestinal stromal tumours","volume":"19","author":"Klug","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2025.01010","article-title":"Vimseltinib: a novel colony stimulating factor 1 receptor (CSF1R) inhibitor approved for treatment of tenosynovial giant cell tumors (TGCTs)","volume":"14","author":"Dou","year":"2025","journal-title":"Intractable Rare Dis Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.46.5476","article-title":"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma","volume":"31","author":"Dickson","year":"2013","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0058","article-title":"NCCN Guidelines\u00ae Insights: Soft tissue sarcoma, Version 1.2025","volume":"23","author":"von Mehren","year":"2025","journal-title":"J Natl Compr Cancer Network"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00436","article-title":"Survival outcomes of patients with tropomyosin receptor kinase fusion-positive cancer receiving larotrectinib versus standard of care: a matching-adjusted indirect comparison using real-world data","volume":"7","author":"Bokemeyer","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25538","article-title":"Trends in survival for patients with metastatic soft-tissue sarcoma","volume":"117","author":"Italiano","year":"2011","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1931","article-title":"Very long-term survivors among patients with metastatic soft tissue sarcoma","volume":"8","author":"Carbonnaux","year":"2019","journal-title":"Cancer Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010515)91:10<1914::aid-cncr1214>3.0.co;2-3","article-title":"Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group","volume":"91","author":"Coindre","year":"2001","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1186\/s12885-020-07300-7","article-title":"Survival predictors of metastatic angiosarcomas: a surveillance, epidemiology, and end results program population-based retrospective study","volume":"20","author":"Ren","year":"2020","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-020-04647-5","article-title":"Incidence and prognosis of distant metastasis in Malignant peripheral nerve sheath tumors","volume":"163","author":"Xu","year":"2021","journal-title":"Acta Neurochir (Wien)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ygyno.2017.02.012","article-title":"Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0049","article-title":"Clinical actionability of comprehensive genomic profiling for management of rare or refractory cancers","volume":"21","author":"Hirshfield","year":"2016","journal-title":"Oncologist"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1038\/s41467-022-30496-0","article-title":"Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma","volume":"13","author":"Gounder","year":"2022","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051156","article-title":"Impact and diagnostic gaps of comprehensive genomic profiling in real-world clinical practice","volume":"12","author":"Singh","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2021.08.005","article-title":"Development and validation of StrataNGS, a multiplex PCR, semiconductor sequencing-based comprehensive genomic profiling test","volume":"23","author":"Tomlins","year":"2021","journal-title":"J Mol Diagn"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"key":"B20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41698-021-00202-2","article-title":"Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA","volume":"5","author":"Finkle","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"B21","unstructured":"Guardant360 Cdx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers\n          \n          2020"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.10.007","article-title":"Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib","volume":"166","author":"Bauml","year":"2022","journal-title":"Lung Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.17925\/ohr.2022.18.1.73","article-title":"Maximizing immunotherapy in sarcoma using histology, biomarkers and novel approaches","volume":"18","author":"Stein","year":"2022","journal-title":"touchREVIEWS Oncol Haematology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-3485","article-title":"Histologic and immunologic factors associated with response to immune checkpoint inhibitors in advanced sarcoma","volume":"31","author":"Lee","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","article-title":"Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution","volume":"7","author":"Florou","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004149","article-title":"Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center","volume":"10","author":"Rosenbaum","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.843707","article-title":"Hyperprogressive disease in patients suffering from solid Malignancies treated by immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6970","article-title":"Incidence of immunotherapy-related hyperprogressive disease (HPD) across HPD definitions and cancer types in observational studies: a systematic review and meta-analysis","volume":"13","author":"Kim","year":"2024","journal-title":"Cancer Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"B31","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Soft Tissue Sarcoma. Version 1.2026","year":"2026"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/po-24-00401","article-title":"Next-generation sequencing-guided treatment of BRCA2-mutant metastatic uterine leiomyosarcoma with poly(ADP-ribose) polymerase inhibitor therapy","volume":"8","author":"Kirkendoll","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003464","article-title":"Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types","volume":"9","author":"Giacomini","year":"2013","journal-title":"PloS Genet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1038\/s41467-022-30453-x","article-title":"Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets","volume":"13","author":"Nacev","year":"2022","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/cup.13926","article-title":"Spindle cell tumor with CD34 and S100 co-expression and distinctive stromal and perivascular hyalinization showing EML4-ALK fusion","volume":"48","author":"Abs","year":"2021","journal-title":"J Cutan Pathol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/gcc.23097","article-title":"ALK-rearranged mesenchymal neoplasms: a report of 9 cases further expanding the clinicopathologic spectrum of emerging kinase fusion positive group of tumors","volume":"62","author":"Dermawan","year":"2023","journal-title":"Genes Chromosomes Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00402","article-title":"Phase II study of olaparib and temozolomide for advanced uterine leiomyosarcoma (NCI Protocol 10250)","volume":"41","author":"Ingham","year":"2023","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.lungcan.2020.03.005","article-title":"Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer","volume":"143","author":"Sheinson","year":"2020","journal-title":"Lung Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/op-24-00936","article-title":"Timeliness of newer targeted therapy and survival in lung cancer: a population-based analysis","volume":"22","author":"Tanvetyanon","year":"2026","journal-title":"JCO Oncol Pract"},{"key":"B40","article-title":"Prior authorization: patient involvement and time burden in cancer treatment","volume-title":"Jco Oncology Practice","author":"Alexandra","year":"2025"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0075","article-title":"ALK-rearranged non-small cell lung cancer in 2020: real-world triumphs in an era of multigeneration ALK-inhibitor sequencing informed by drug resistance profiling","volume":"25","author":"Itchins","year":"2020","journal-title":"Oncologist"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-1824","article-title":"Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab","volume":"26","author":"Keung","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.11503","article-title":"A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902)","volume":"41","author":"Grilley-Olson","year":"2023","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-2580","article-title":"Validation of a seven-gene predictive SIGNature for the efficacy of immuno-oncology PD-1 inhibitors in patients with sarcoma","volume":"32","author":"Moura","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.5585","article-title":"Trends and disparities in the use of next-generation sequencing in patients with cancer in the United States","volume":"9","author":"Hage Chehade","year":"2026","journal-title":"JAMA Netw Open"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02534-0","article-title":"SEOM Clinical Guideline of management of soft-tissue sarcoma (2020)","volume":"23","author":"de Juan Ferre","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02721-8","article-title":"Introduction and impact of routine whole genome sequencing in the diagnosis and management of sarcoma","volume":"131","author":"Watkins","year":"2024","journal-title":"Br J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02767","article-title":"Somatic genomic testing in patients with metastatic or advanced cancer: ASCO Provisional Clinical Opinion","volume":"40","author":"Chakravarty","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1842108\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:26:45Z","timestamp":1782707205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1842108\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":49,"alternative-id":["10.3389\/fonc.2026.1842108"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1842108","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"article-number":"1842108"}}